UA140070U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of endothelin, folic acid, C-reactive protein (SRP), glycosaminoglycans (GAG). With a homozygous carrier of 677-TT and levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, PSA> 6 mg / l, GAG> 28 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model, a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology, and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, folic acid, C-reactive protein (CRP), and glycosaminoglycans (GAG) are determined in the patient's blood serum. and with homozygous carrier 677-TT, endothelin content 210 ng/ml, folic acid "6 ng/ml,

SRP »6 mg/l, GAG »28 μmol/l predict the development of osteoarthritis.

Application of the method. Upon admission, the patient is examined, x-rays are performed, and the MTNEK C677T gene polymorphism is determined. The content of endothelin, folic acid, SRP, GAG is determined by immunoenzymatic method. With homozygous carrier 677-TT, levels of endothelin "10 ng/ml, folic acid "6 ng/ml, SRP 26 mg/l, GAG "28 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient G., 58 years old, went to the clinic for a pain syndrome in the left knee joint. X-rays were examined and performed. No signs of osteoarthritis were found. The MTNEK C677T gene polymorphism was determined in blood serum. The content of endothelin, folic acid, SRP, GAG was determined by immunoenzymatic method. Homozygous carrier 677-1T was established. Levels of endothelin - 20 ng/ml, folic acid - 2.9 ng/ml, SRP - 16 mg/l, GAG - 46 μmol/l.

The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, folic acid, C-reactive protein (CRP), glycosaminoglycans (GAG) and others are determined with homozygous carrier 677-111 and levels of endothelin "10 ng/ml, folic acid "b ng/ml, SRP "6b mg/l, GAG "28 μmol/l predict the development of osteoarthritis.